Meena Arora

Meena Arora is a distinguished Global Medical Affairs Drug Development Scientist working as Vice President Global Medical Affairs and Research and Development focussed on Cancer Research.  She has over two decades of experience in the pharmaceutical and biotechnology sectors. With a keen focus on advancing innovative therapies, Meena has dedicated her career to bridging the gap between science and patient care, ensuring that ground-breaking treatments reach those in need.

Her expertise spans haemato-oncology, cancer therapies, cell/gene therapies, and rare diseases. She has worked with MHRA, EMA, and FDA, and Health Technology Appraisal committees (e.g. NICE) leading to successful global drug approval and access.

Born in Newcastle Upon Tyne, she has worked in various small and large biotech and pharmaceutical companies working in UK, and in European and Global/ International roles.

Meena played a pivotal role in the development of the first globally approved drug for Epidermolysis Bullosa in 2023 – a rare genetic disease where no therapies were available.

She has contributed to over 60 clinical studies involving 25,000+ patients and has spearheaded advances in oncology and investigator research projects, and been involved in scientific developments including cell therapies including CAR-T therapy for cancer.

She also serves as a mentor, promotes diversity in healthcare, and is a visiting lecturer in Drug Development and Pharmaceutical Medicine at King’s College London.

Meena is an author of scientific papers and been involved in numerous peer-reviewed articles and presented globally. She founded Arora Global Solutions Ltd., a consultancy for pharmaceutical medical and scientific strategy and operations, focusing on cancer and rare diseases.

Outside work, she enjoys traveling, spinning, music, dancing, and spending time with her children, Jay and Zara.